EP4232045A4 - Zusammensetzungen aus berberin-ursodeoxycholat und verfahren dafür zur behandlung von fettlebererkrankung, diabetes und hyperlipidämie - Google Patents

Zusammensetzungen aus berberin-ursodeoxycholat und verfahren dafür zur behandlung von fettlebererkrankung, diabetes und hyperlipidämie Download PDF

Info

Publication number
EP4232045A4
EP4232045A4 EP21882127.0A EP21882127A EP4232045A4 EP 4232045 A4 EP4232045 A4 EP 4232045A4 EP 21882127 A EP21882127 A EP 21882127A EP 4232045 A4 EP4232045 A4 EP 4232045A4
Authority
EP
European Patent Office
Prior art keywords
hyperlipidemia
diabetes
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21882127.0A
Other languages
English (en)
French (fr)
Other versions
EP4232045A1 (de
Inventor
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hightide Biopharmaceutical Ltd
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of EP4232045A1 publication Critical patent/EP4232045A1/de
Publication of EP4232045A4 publication Critical patent/EP4232045A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21882127.0A 2020-10-23 2021-10-22 Zusammensetzungen aus berberin-ursodeoxycholat und verfahren dafür zur behandlung von fettlebererkrankung, diabetes und hyperlipidämie Pending EP4232045A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104754P 2020-10-23 2020-10-23
PCT/CN2021/125490 WO2022083713A1 (en) 2020-10-23 2021-10-22 Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia

Publications (2)

Publication Number Publication Date
EP4232045A1 EP4232045A1 (de) 2023-08-30
EP4232045A4 true EP4232045A4 (de) 2024-09-04

Family

ID=81289703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21882127.0A Pending EP4232045A4 (de) 2020-10-23 2021-10-22 Zusammensetzungen aus berberin-ursodeoxycholat und verfahren dafür zur behandlung von fettlebererkrankung, diabetes und hyperlipidämie

Country Status (3)

Country Link
EP (1) EP4232045A4 (de)
CN (1) CN116782898A (de)
WO (1) WO2022083713A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088463A1 (en) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19
WO2024169937A1 (en) * 2023-02-15 2024-08-22 Shenzhen Hightide Biopharmaceutical Ltd. Berberine tauroursodeoxycholate compositions and methods thereof
WO2024179570A1 (en) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating severe hypertriglyceridemia
WO2025130826A1 (en) * 2023-12-18 2025-06-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Compositions and methods for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011420A1 (ja) * 2007-07-18 2009-01-22 Mitsubishi Tanabe Pharma Corporation ２型糖尿病の治療薬
WO2010106420A1 (en) * 2009-03-17 2010-09-23 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011420A1 (ja) * 2007-07-18 2009-01-22 Mitsubishi Tanabe Pharma Corporation ２型糖尿病の治療薬
WO2010106420A1 (en) * 2009-03-17 2010-09-23 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LI ZHAO ET AL: "Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease", BMC ENDOCRINE DISORDERS, BIOMED CENTRAL LTD, LONDON, UK, vol. 17, no. 1, 28 February 2017 (2017-02-28), pages 1 - 8, XP021242660, DOI: 10.1186/S12902-017-0165-7 *
LIU L ET AL: "HTD1801 a novel treatment addressing the underlying metabolic features of NAFLD/NASH", HEPATOLOGY V70 SUPPL.1 2019 20191001 JOHN WILEY AND SONS INC. NLD, vol. 70, no. Supplement 1, 1 October 2019 (2019-10-01), XP009555841, ISSN: 1527-3350 *
LIU, LP; BAI, R; YU, L; YU, M; FU, XX: "HTD1801 A NOVEL TREATMENT FOR NAFLD/NASH AND PRIMARY SCLEROSING CHOLANGITIS (PSC)", HEPATOLOGY, vol. 70, no. Suppl 1, 1 October 2019 (2019-10-01), pages 1261A - 1262A, XP009555813 *
See also references of WO2022083713A1 *
XING LIAN-JUN ET AL: "Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 668, no. 3, 1 October 2011 (2011-10-01), NL, pages 467 - 471, XP093189113, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.07.036 *
ZHANG HAO ET AL: "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression", METABOLISM, vol. 59, no. 2, 1 February 2010 (2010-02-01), US, pages 285 - 292, XP093189125, ISSN: 0026-0495, DOI: 10.1016/j.metabol.2009.07.029 *

Also Published As

Publication number Publication date
WO2022083713A1 (en) 2022-04-28
CN116782898A (zh) 2023-09-19
EP4232045A1 (de) 2023-08-30

Similar Documents

Publication Publication Date Title
EP4232045A4 (de) Zusammensetzungen aus berberin-ursodeoxycholat und verfahren dafür zur behandlung von fettlebererkrankung, diabetes und hyperlipidämie
EP4281464A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechsel- und lebererkrankungen
EP4373939A4 (de) Genomeditierungszusammensetzungen und verfahren zur behandlung von chronischer granulomatöser erkrankung
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP4415755A4 (de) Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19
EP3866852A4 (de) Zusammensetzungen und verfahren zur behandlung von lebererkranungen
EP4204443A4 (de) Verfahren und zusammensetzungen zur behandlung von glioblastom
EP4384219A4 (de) Zusammensetzungen, dosen und verfahren zur behandlung von schilddrüsenaugenkrankheit
EP4413137A4 (de) Zusammensetzungen und verfahren zur behandlung von cag-wiederholungserkrankungen
EP3740592A4 (de) Verfahren und zusammensetzungen zur behandlung von gefässerkrankungen
EP3986439A4 (de) Zusammensetzungen und verfahren zur behandlung von hirnerkrankungen
EP3781158A4 (de) Zusammensetzungen zur behandlung von nicht-alkoholischer fettlebererkrankung und nicht-alkoholischer steatohepatitis
EP4401745A4 (de) Verfahren und verwendungen von mikrobiomzusammensetzungen, komponenten oder metaboliten zur behandlung neurodegenerativer erkrankungen
EP4045094A4 (de) Zusammensetzungen und verfahren zur behandlung von lebererkrankung
EP3990018A4 (de) Verfahren und zusammensetzungen zur behandlung von morbus alzheimer
EP4340860A4 (de) Zusammensetzungen und verfahren zur behandlung von neuropathie
EP4188346A4 (de) Nobiletinzusammensetzungen und verfahren zur behandlung und prävention von covid-19 und verwandten erkrankungen
EP4034109A4 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen
EP4025199A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus alzheimer
EP2142566A4 (de) Verfahren und zusammensetzungen zur behandlung von proliferativen krankheiten
EP4340835A4 (de) Verfahren und zusammensetzungen zur behandlung von herz-kreislauf-erkrankungen
EP4340897A4 (de) Verfahren und zusammensetzungen zur behandlung von pankreas- und lebererkrankungen
EP4478887A4 (de) Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit
EP4114438A4 (de) Verfahren und zusammensetzungen zur behandlung von muskelatrophie
EP4412632A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240806

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20240731BHEP

Ipc: A61K 9/20 20060101ALI20240731BHEP

Ipc: A61P 3/10 20060101ALI20240731BHEP

Ipc: A61P 3/06 20060101ALI20240731BHEP

Ipc: A61P 1/16 20060101ALI20240731BHEP

Ipc: A61K 31/4375 20060101ALI20240731BHEP

Ipc: A61K 31/575 20060101AFI20240731BHEP